Citations (46)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Zhaohua Zhu, Jia Li, Guangfeng Ruan, Guoliang Wang, Cibo Huang & Changhai Ding. (2018) Investigational drugs for the treatment of osteoarthritis, an update on recent developments. Expert Opinion on Investigational Drugs 27:11, pages 881-900.
Read now
Read now
Paul W. H. I. Parren, Paul J. Carter & Andreas Plückthun. (2017) Changes to International Nonproprietary Names for antibody therapeutics 2017 and beyond: of mice, men and more. mAbs 9:6, pages 898-906.
Read now
Read now
Kenta Haraya, Tatsuhiko Tachibana & Junichi Nezu. (2017) Predicting pharmacokinetic profile of therapeutic antibodies after iv injection from only the data after sc injection in cynomolgus monkey. Xenobiotica 47:3, pages 194-201.
Read now
Read now
Ulrich Brinkmann & Roland E. Kontermann. (2017) The making of bispecific antibodies. mAbs 9:2, pages 182-212.
Read now
Read now
Shuang Zheng, David J. Hunter, Jianhua Xu & Changhai Ding. (2016) Monoclonal antibodies for the treatment of osteoarthritis. Expert Opinion on Biological Therapy 16:12, pages 1529-1540.
Read now
Read now
Lieven Pouillon, Peter Bossuyt & Laurent Peyrin-Biroulet. (2016) Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease. Expert Opinion on Biological Therapy 16:10, pages 1277-1290.
Read now
Read now
Kang Wang, Jianhua Xu, David J Hunter & Changhai Ding. (2015) Investigational drugs for the treatment of osteoarthritis. Expert Opinion on Investigational Drugs 24:12, pages 1539-1556.
Read now
Read now
Articles from other publishers (39)
Mohit Kumar, Raghav Dogra & Uttam Kumar Mandal. (2023) Novel Formulation Approaches used for the Management of Osteoarthritis: A Recent Review. Current Drug Delivery 20:7, pages 841-856.
Crossref
Crossref
Ziqi Zhang, Xue Li, Yang Wang, Yuquan Wei & Xiawei Wei. (2023) Involvement of inflammasomes in tumor microenvironment and tumor therapies. Journal of Hematology & Oncology 16:1.
Crossref
Crossref
Lizhi Yu, Raoshan Luo, Gang Qin, Qinyan Zhang & Weiming Liang. (2023) Efficacy and safety of anti-interleukin-1 therapeutics in the treatment of knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials. Journal of Orthopaedic Surgery and Research 18:1.
Crossref
Crossref
Rebecca C. Coll. 2023. Inflammasome Biology. Inflammasome Biology
583
603
.
Lennart Ocker, Nessr Abu Rached, Caroline Seifert, Christina Scheel & Falk G. Bechara. (2022) Current Medical and Surgical Treatment of Hidradenitis Suppurativa—A Comprehensive Review. Journal of Clinical Medicine 11:23, pages 7240.
Crossref
Crossref
Guoqi Cai, Graeme Jones, Flavia M. Cicuttini, Anita E. Wluka, Yuanyuan Wang, Catherine Hill, Helen Keen, Benny Antony, Xia Wang, Barbara de Graaff, Michael Thompson, Tania Winzenberg, Kathy Buttigieg & Dawn Aitken. (2022) Study protocol for a randomised controlled trial of diacerein versus placebo to treat knee osteoarthritis with effusion-synovitis (DICKENS). Trials 23:1.
Crossref
Crossref
Md. Abu Bakar Siddiq, Danny Clegg, Tim L. Jansen & Johannes J. Rasker. (2022) Emerging and New Treatment Options for Knee Osteoarthritis. Current Rheumatology Reviews 18:1, pages 20-32.
Crossref
Crossref
Pamela D. Garzone & Yow-Ming C. Wang. 2022. Atkinson's Principles of Clinical Pharmacology. Atkinson's Principles of Clinical Pharmacology
611
651
.
Asim Ghouri, Jonathan G. Quicke & Philip G. Conaghan. (2021) New developments in osteoarthritis pharmacological therapies. Rheumatology 60:Supplement_6, pages vi1-vi11.
Crossref
Crossref
Asim Ghouri & Philip G. Conaghan. (2020) Prospects for Therapies in Osteoarthritis. Calcified Tissue International 109:3, pages 339-350.
Crossref
Crossref
Xiaoyan Cai, Shiwen Yuan, Yanting Zeng, Cuicui Wang, Na Yu & Changhai Ding. (2021) New Trends in Pharmacological Treatments for Osteoarthritis. Frontiers in Pharmacology 12.
Crossref
Crossref
Paola Galozzi, Sara Bindoli, Andrea Doria & Paolo Sfriso. (2021) The revisited role of interleukin-1 alpha and beta in autoimmune and inflammatory disorders and in comorbidities. Autoimmunity Reviews 20:4, pages 102785.
Crossref
Crossref
Mehdi Mohammadi, Mahmood Jeddi-Tehrani, Forough Golsaz-Shirazi, Mohammad Arjmand, Tannaz Bahadori, Mohammad Ali Judaki, Fariba Shiravi, Hengameh Ahmadi Zare, Farzaneh Notash Haghighat, Maryam Mobini, Mohammad Mehdi Amiri & Fazel Shokri. (2021) A Novel Anti-HER2 Bispecific Antibody With Potent Tumor Inhibitory Effects In Vitro and In Vivo. Frontiers in Immunology 11.
Crossref
Crossref
Xianlai Chen, Mingyue Xu & Ying An. (2021) Identifying the essential nodes in network pharmacology based on multilayer network combined with random walk algorithm. Journal of Biomedical Informatics 114, pages 103666.
Crossref
Crossref
Kenta Haraya & Tatsuhiko Tachibana. (2020) Simple Approach to Accurately Predict Pharmacokinetics of Therapeutic Monoclonal Antibodies after Subcutaneous Injection in Humans. Clinical Pharmacokinetics 60:1, pages 111-120.
Crossref
Crossref
Ziqin Cao, Yajia Li, Wanchun Wang, Shuo Jie, Xuantao Hu, Jian Zhou, Tong Wu, Dilihumaer Aili, Zeling Long, Yihan Li, Pengcheng Dou & Ren Wu. (2020) Is Lutikizumab, an Anti–Interleukin-1α/β Dual Variable Domain Immunoglobulin, efficacious for Osteoarthritis? Results from a bayesian network meta-analysis. BioMed Research International 2020, pages 1-10.
Crossref
Crossref
Enrico Ragni, Laura Mangiavini, Marco Viganò, Anna Teresa Brini, Giuseppe Michele Peretti, Giuseppe Banfi & Laura de Girolamo. (2020) Management of Osteoarthritis During the COVID‐19 Pandemic. Clinical Pharmacology & Therapeutics 108:4, pages 719-729.
Crossref
Crossref
Navnit S. Makaram, Marc R. Safran, Geoffrey D. Abrams, Seth L. Sherman & Iain R. Murray. (2020) Rationale for the Use of Orthobiologics in Sports Medicine. Operative Techniques in Sports Medicine 28:3, pages 150753.
Crossref
Crossref
Sung In Lim. (2020) Fine-tuning bispecific therapeutics. Pharmacology & Therapeutics 212, pages 107582.
Crossref
Crossref
Yan Hao, Xinhang DongMingzi Zhang, Hao Liu, Lin Zhu & Youbin Wang. (2020) Effects of hyperbaric oxygen therapy on the expression levels of the inflammatory factors interleukin-12p40, macrophage inflammatory protein-1β, platelet-derived growth factor-BB, and interleukin-1 receptor antagonist in keloids. Medicine 99:16, pages e19857.
Crossref
Crossref
Mark L. Chiu, Dennis R. Goulet, Alexey Teplyakov & Gary L. Gilliland. (2019) Antibody Structure and Function: The Basis for Engineering Therapeutics. Antibodies 8:4, pages 55.
Crossref
Crossref
Feng Dong & Tariq Ghayur. (2019) Recent advancements in DVD-Ig based therapeutic development. Drug Discovery Today: Technologies 34, pages 1-7.
Crossref
Crossref
Charles Anthony Dinarello. (2019) The IL-1 family of cytokines and receptors in rheumatic diseases. Nature Reviews Rheumatology 15:10, pages 612-632.
Crossref
Crossref
María José Alcaraz, María Isabel Guillén & María Luisa Ferrándiz. (2019) Emerging therapeutic agents in osteoarthritis. Biochemical Pharmacology 165, pages 4-16.
Crossref
Crossref
Roy M. Fleischmann, Henning Bliddal, Francisco J. Blanco, Thomas J. Schnitzer, Charles Peterfy, Su Chen, Li Wang, Sheng Feng, Philip G. Conaghan, Francis Berenbaum, Jean‐Pierre Pelletier, Johanne Martel‐Pelletier, Ole Vaeterlein, Gurjit S. Kaeley, Wei Liu, Matthew P. Kosloski, Gwen Levy, Lanju Zhang, Jeroen K. Medema & Marc C. Levesque. (2019)
A Phase
II
Trial of Lutikizumab, an Anti–Interleukin‐1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis
. Arthritis & Rheumatology 71:7, pages 1056-1069.
Crossref
Crossref
Sinead Ahern & Anders Cervin. (2019) Inflammation and Endotyping in Chronic Rhinosinusitis—A Paradigm Shift. Medicina 55:4, pages 95.
Crossref
Crossref
Margreet Kloppenburg, Charles Peterfy, Ida K Haugen, Féline Kroon, Su Chen, Li Wang, Wei Liu, Gwen Levy, Roy M Fleischmann, Francis Berenbaum, Désirée van der Heijde, Prashant Bansal, Ruth Wittoek, Sheng Feng, Yuni Fang, Mary Saltarelli, Jeroen K Medema & Marc C Levesque. (2019) Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis. Annals of the Rheumatic Diseases 78:3, pages 413-420.
Crossref
Crossref
Shixue Chen, Lingling Li, Fan Zhang, Yu Wang, Yi Hu & Lei Zhao. (2019) Immunoglobulin Gamma-Like Therapeutic Bispecific Antibody Formats for Tumor Therapy. Journal of Immunology Research 2019, pages 1-13.
Crossref
Crossref
Jonathan Yip, Eric Monteiro & Yvonne Chan. (2019) Endotypes of chronic rhinosinusitis. Current Opinion in Otolaryngology & Head & Neck Surgery 27:1, pages 14-19.
Crossref
Crossref
Asim Ghouri & Philip G. Conaghan. (2019) Update on novel pharmacological therapies for osteoarthritis. Therapeutic Advances in Musculoskeletal Disease 11, pages 1759720X1986449.
Crossref
Crossref
Wenxin Zhao. The research and development of bispecific antibodies. The research and development of bispecific antibodies.
Kristine A. Smith, Abigail Pulsipher, David A. Gabrielsen & Jeremiah A. Alt. (2018) Biologics in Chronic Rhinosinusitis: An Update and Thoughts for Future Directions. American Journal of Rhinology & Allergy 32:5, pages 412-423.
Crossref
Crossref
Melanie C. Ruzek, Lili Huang, Ting- Ting Zhang, Shaughn Bryant, Peter F. Slivka, Carolyn A. Cuff, Catherine Tripp & Guenter Blaich. (2018)
Dual Blockade of Interleukin-1
β
and Interleukin-17A Reduces Murine Arthritis Pathogenesis but Also Leads to Spontaneous Skin Infections in Nonhuman Primates
. Journal of Pharmacology and Experimental Therapeutics 364:3, pages 474-484.
Crossref
Crossref
S.X. Wang, S.B. Abramson, M. Attur, M.A. Karsdal, R.A. Preston, C.J. Lozada, M.P. Kosloski, F. Hong, P. Jiang, M.J. Saltarelli, B.A. Hendrickson & J.K. Medema. (2017) Safety, tolerability, and pharmacodynamics of an anti-interleukin-1α/β dual variable domain immunoglobulin in patients with osteoarthritis of the knee: a randomized phase 1 study. Osteoarthritis and Cartilage 25:12, pages 1952-1961.
Crossref
Crossref
Kenta Haraya, Tatsuhiko Tachibana & Junichi Nezu. (2017) Quantitative prediction of therapeutic antibody pharmacokinetics after intravenous and subcutaneous injection in human. Drug Metabolism and Pharmacokinetics 32:4, pages 208-217.
Crossref
Crossref
Alain C. Tissot & Ulrich Brinkmann. 2017. Next-Generation Therapies and Technologies for Immune-Mediated Inflammatory Diseases. Next-Generation Therapies and Technologies for Immune-Mediated Inflammatory Diseases
75
97
.
M.A. Karsdal, M. Michaelis, C. Ladel, A.S. Siebuhr, A.R. Bihlet, J.R. Andersen, H. Guehring, C. Christiansen, A.C. Bay-Jensen & V.B. Kraus. (2016) Disease-modifying treatments for osteoarthritis (DMOADs) of the knee and hip: lessons learned from failures and opportunities for the future. Osteoarthritis and Cartilage 24:12, pages 2013-2021.
Crossref
Crossref
Anne-Marie Malfait & Richard J. Miller. (2016) Emerging Targets for the Management of Osteoarthritis Pain. Current Osteoporosis Reports 14:6, pages 260-268.
Crossref
Crossref
Matthew P. Kosloski, Sandra Goss, Susanne X. Wang, Jia Liu, Ralf Loebbert, Jeroen K. Medema, Wei Liu & Sandeep Dutta. (2016) Pharmacokinetics and Tolerability of a Dual Variable Domain Immunoglobulin ABT‐981 Against IL‐1α and IL‐1β in Healthy Subjects and Patients With Osteoarthritis of the Knee. The Journal of Clinical Pharmacology 56:12, pages 1582-1590.
Crossref
Crossref